 Aeglea BioTherapeutics, Inc. AGLE, a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will present a new 56 week analysis on patients who have been treated with pegzilarginase from the completed Phase 12 clinical trial and the ongoing Phase 2 open-label extension study in a late-breaking oral presentation at the 6th Congress of the European Academy of Neurology being held virtually May 23-26, 2020. Pegzilarginase is an enhanced human arginase that enzymatically lowers levels of the amino acid arginine. Aeglea is developing pegzilarginase for the treatment of patients with Arginase 1 Deficiency ARG1-D, a rare debilitating disease presenting in childhood with persistent hyperargininemia, severe progressive neurological abnormalities and early mortality. 